News

Novel biomarker found in ovarian cancer patients can predict response to therapy

Synopsis: In the September 20, 2018 issue of the biomedical journal Cell, research teams from the University of Chicago Medicine; the Max Plank Institute of Biochemistry in Martinsried/ Munich, Germany; and the Novo Nordisk Foundation Center for Protein Research in Copenhagen, Denmark, identify an independent prognostic factor — cancer/testis antigen 45 – and began to elucidate its actions.

Read the press release on a study from the Lengyel Lab with research teams from tMax Plank Institute and the Novo Nordisk Foundation Center for Protein Research "Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer" published in the Sept., 2018 issue of Cell

Click here to view the full story 

The Department of Obstetrics and Gynecology